Navigation Links
Lung Cancer Microscopic Appearance Affects Response to Chemotherapy
Date:2/17/2009

Tumor Structure Should Be Considered in Treating NSCLC, Says Report in "The Oncologist"

DURHAM, N.C., Feb. 17 /PRNewswire/ -- A tumor's cellular structure, or histology, improves treatment decisions that may lead to improved outcomes for patients with non-small cell lung cancer (NSCLC), the most common type of lung cancer, according to a paper in the latest issue of "The Oncologist."

(Logo: http://www.newscom.com/cgi-bin/prnh/20080627/CLF051LOGO )

The findings are based on an analysis of recent studies of the chemotherapy drug pemetrexed to treat NSCLC. "The data confirm that histology matters when treating NSCLC," says Professor Giorgio Scagliotti, M.D., of University of Turin, lead author of the new report.

Prof. Scagliotti and colleagues analyzed data from two recent phase III studies of pemetrexed for NSCLC, which accounts for about 90 percent of all lung cancers. They focused on how differences in cancer histology affect the response to treatment with pemetrexed. The histology of a cancer is its microscopic cellular structure and in NSCLC, tumors may be classified as having a "squamous" or "non-squamous" appearance.

Their analysis showed significant differences in response to pemetrexed between these two lung cancer subtypes. Specifically, pemetrexed was more effective than current forms of chemotherapy against cancers with a non-squamous histology. For these patients, pemetrexed led to significant improvements in overall survival and in survival without progressive cancer. In contrast, for patients whose cancers had the squamous histology, outcomes were similar with or without pemetrexed.

The two studies were a "frontline" trial including patients with previously untreated NSCLC and a "second-line" trial including patients with previous chemotherapy. The interaction between cancer histology and response to pemetrexed was similar in both groups of patients. Based on the results of the frontline trial, pemetrexed has been approved for initial treatment of NSCLC in Europe, Canada and the United States, in combination with cisplatin, another chemotherapy drug.

In the past, cancer histology hasn't been considered in selecting treatments for patients with NSCLC. "For more than 25 years medical oncologists have simply looked at the distinction between small-cell and non-small-cell lung cancer in making systemic treatment decisions," says Prof. Scagliotti. "This is because there has previously been no convincing evidence that the available treatments have any differential activity based on the histologic subtype of NSCLC." "On the basis of these studies, tumor histology should be carefully assessed when selecting treatment options for patients with advanced NSCLC," says Prof. Scagliotti.

The article entitled "The Differential Efficacy of Pemetrexed According to NSCLC Histology: A Review of Two Phase III Studies," has been published by "The Oncologist," and is freely available online at:

http://theoncologist.com/cgi/content/abstract/theoncologist.2008-0232v1

About AlphaMed Press

AlphaMed Press publishes the internationally renowned journals, "Stem Cells" and "The Oncologist." "Stem Cells," now in its 27th year, is the oldest and one of the world's top-tier peer-reviewed monthly journals in the fast-paced area of stem cells and regenerative medicine. "The Oncologist," in its 14th year, is a premier peer-reviewed monthly journal dedicated to physicians entrusted with the care of cancer patients. View AlphaMed Press journals at http://www.alphamedpress.org

Contact: Dr. Martin J. Murphy, Executive Editor: 919.402.8750, Martin.Murphy@TheOncologist.com


'/>"/>
SOURCE AlphaMed Press
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Targeting the protein AEG1 impairs human liver cancer growth in mice
2. Hodgkins Survivors Prone to Breast Cancer Later
3. Social Disconnection in African American Women With Breast Cancer
4. Researchers ID Biomarker for Fatal Prostate Cancer
5. Teens with cancer present unique psychological issues
6. SpectraScience Secures Distribution for WavSTAT(R) Cancer Diagnosis System in Greece & Cyprus
7. New Anti-Clotting Treatment Urged for Cancer Patients
8. Fruit flies soar as lab model, drug screen for the deadliest of human brain cancers
9. Normalizing tumor vessels leaves cancer more benign
10. Womens cancer outcomes improved by surgical evaluation
11. Pediatric Hodgkins disease survivors face increased breast cancer risk
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... June 25, 2016 , ... Austin residents seeking Mohs surgery ... of Mohs Surgery and to Dr. Russell Peckham for medical and surgical dermatology. , ... for skin cancer. The selective fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... ... athletes and non-athletes recover from injury. Recently, he has implemented orthobiologic procedures as ... City area —Johnson is one of the first doctors to perform the treatment. ...
(Date:6/24/2016)... , ... June 24, 2016 , ... June 19, 2016 ... dangers associated with chronic pain and the benefits of holistic treatments, Serenity Recovery ... are suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) is a disorder ...
(Date:6/24/2016)... ... June 24, 2016 , ... Comfort Keepers® of San Diego, CA ... the Road To Recovery® program to drive cancer patients to and from their cancer ... ensure the highest quality of life and ongoing independence. Getting to and from ...
(Date:6/24/2016)... ... June 24, 2016 , ... Puradigm® ... Group (TGIG), has initiated cultivation and processing operations at its production facility, and ... Nevada. , Puradigm is the manufacturer of a complete system of proactive air ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... -- Research and Markets has announced the addition ... 2022" report to their offering. ... with kidney failure, it replaces the function of kidneys by ... and thus the treatment helps to keep the patient body,s ... Increasing number of ESRD patients & substantial healthcare ...
(Date:6/23/2016)... 2016  In a startling report released today, National Safety ... lacking a comprehensive, proven plan to eliminate prescription opioid overdoses. ... how states are tackling the worst drug crisis in recorded U.S. ... Kentucky , New Mexico , ... Of the 28 failing states, three – Michigan ...
(Date:6/23/2016)... June 23, 2016 Capricor ... ), a biotechnology company focused on the discovery, ... that patient enrollment in its ongoing randomized HOPE-Duchenne ... exceeded 50% of its 24-patient target. Capricor expects ... third quarter of 2016, and to report top ...
Breaking Medicine Technology: